This is one of the questions clients ask most often, and the social-media coverage of PDGF lately has not made it easier to answer. The short version: Ariessence Pure PDGF is a topical product, applied to the skin after a procedure that creates microchannels — most commonly SkinPen microneedling or fractional laser.
It is not delivered by injection in our standard public-facing protocol. There are advanced applications we discuss in consultation, but the protocol most clients receive — and the one our results and recommendations are built around — is topical. The longer version is more interesting, and worth understanding if you're considering this treatment or comparing providers.
What PDGF actually is
PDGF stands for platelet-derived growth factor. It is a signaling protein the body releases at sites of injury to recruit fibroblasts — the cells that build new collagen and reorganize the dermis during healing. It is one of the active ingredients in your own platelets, which is why PRP and PRF therapies have been used in aesthetics for years. PDGF is, in a sense, the molecule the body itself uses to repair skin.
Ariessence Pure PDGF+ is a recombinant version: bioengineered, clinical-grade purity, at a standardized concentration. The benefit of the recombinant form over PRP is consistency — you get the same dose every visit, rather than the natural variability of whatever your platelets happen to contain that day.
How it's classified by the FDA
The four FDA-approved PDGF-containing medical products on the market — GEM 21S®, Augment®, Augment® Injectable, and Regranex® — are approved for specific non-cosmetic indications: periodontal regeneration, bone graft augmentation, and diabetic foot ulcer wound healing. These are not the same product as Ariessence; they are referenced here to show that PDGF as a molecule has a substantial FDA-approved track record in medicine, just not in cosmetic aesthetics.
Ariessence Pure PDGF+ itself is filed with the FDA as a cosmetic product. Like all cosmetic products, pre-market FDA approval is not required for this classification. The manufacturer's labeling and marketing position is that it is intended for topical use, post-procedure. We follow that intended use.
How we use Ariessence at Privé
The fundamental challenge with any topically applied protein is delivery. Skin's outermost barrier — the stratum corneum — is designed to prevent large molecules from getting through. Apply growth factor to intact skin, and it largely sits on the surface. The fibroblasts that need to receive that signal are several microns deeper, in the upper dermis.
Microchannels solve this. A SkinPen microneedling pass — or, for some clients, RF microneedling, fractional laser, or a medium-depth chemical peel — creates thousands of tiny vertical channels that bypass the stratum corneum and reach the upper dermis. While those channels are fresh, topical Ariessence is applied. The growth factor reaches the cells that can use it.
This is the protocol that has clinical evidence behind it. The Gold 2025 randomized controlled trial — the strongest available study on topical PDGF in aesthetics — paired recombinant PDGF with Morpheus8 radiofrequency microneedling and showed statistically significant skin improvement at 30 days versus a bland emollient control. The principle is the same with SkinPen: open the channels, deliver the signal.
So why do some clinics describe PDGF as an injection?
You will see this on competitor websites in Dallas and beyond, and it is reasonable to wonder why some providers describe an "injection" and others describe a "topical." A few honest answers.
Some providers do offer PDGF injection. It is a procedure that exists, in studios where the clinician has decided it is appropriate for their practice. It is not, in our reading of the regulatory environment and the available clinical evidence, the same risk profile as the topical-with-microchannels protocol. The legal and clinical literature on this is still emerging. Some providers are comfortable with that uncertainty; others are not.
Some descriptions conflate the procedure with the underlying microneedling. A SkinPen session involves a needling device, even if no fluid is being injected through a syringe. The marketing language can blur into "PDGF injection" when what is actually happening is topical PDGF after microneedling. This is not deception — it's just imprecise language. We try to be precise.
The strongest clinical voices in aesthetics — including the plastic surgeons who first published on Ariessence — describe it as a topical post-procedure product. That is the framing we follow. Dr. Frank Agullo, MD, who has written one of the most thorough clinical reads on Ariessence and the Gold trial, puts it this way: "Topical PDGF on intact skin is a moisturizer with an interesting label. The post-procedure microchannels are what enable dermal delivery."
What about clients who specifically want injection?
We have this conversation in person, in consultation. There are advanced applications of PDGF that some clients have read about and ask for specifically. The consultation conversation includes: what the clinical evidence actually supports for any given indication, what the regulatory environment for those advanced applications is, what risks the published literature describes (granulomas and nodules are documented), what the insurance and informed-consent considerations are, and what your alternatives are.
We are equipped to have that conversation honestly. We are not equipped to have it in writing on a public marketing page. The result is that the right answer for many clients is the topical-with-SkinPen protocol — clinically validated, manufacturer-intended, defensible. For some clients with specific goals, a different conversation happens in the consultation room.
The summary, for the impatient reader
- Ariessence Pure PDGF is, in our public-facing protocol, applied topically to skin that has been microneedled or otherwise treated to create microchannels.
- This protocol has the strongest available clinical evidence (Gold 2025 RCT, topical PDGF post-Morpheus8).
- The manufacturer markets Ariessence for topical use; the FDA classifies it as a cosmetic product.
- Some competing providers describe PDGF as an "injection." That is a different protocol with different regulatory and clinical considerations, and not what we publicly offer.
- If you have specific questions about advanced applications, those are consultation conversations.
If you want to talk through whether Ariessence + SkinPen is right for you, or compare it with PRP, PRF, EZGel, or another regenerative pathway, the consultation is the right next step.